GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity and type-2 diabetes ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions about the causes of obesity and treatment goals.

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...

The best metric is not weight, but a particularly toxic kind of fat.

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...